Aadi Bioscience (AADI)

• Market cap: $83.6M
• 1 day: 46.12%
• 5 days: 40.66%
• 1 month: 52.70%
• 3 months: 75.65%
• 6 months: 107.98%
• Year to date: 65.37%
• 1 year: 64.56%
• 5 years: -86.96%
• 10 years: -86.96%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

Employees: 53

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

2,350% more call options, than puts

Call options by funds: $49K | Put options by funds: $2K

46% more capital invested

Capital invested by funds: $16.8M [Q2] → $24.7M (+$7.83M) [Q3]

1.65% more ownership

Funds ownership: 46.99% [Q2] → 48.64% (+1.65%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]

20% less funds holding

Funds holding: 65 [Q2] → 52 (-13) [Q3]

57% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 23

68% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 22